Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Sustained efficacy and safety of levodopa-carbidopa intestinal gel in advanced Parkinson's disease: a 10-year observational study.
Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levodopa-Carbidopa Intestinal Gel (LCIG) provides continuous dopaminergic stimulation for patients with advanced Parkinson’s disease (aPD) and is particularly beneficial for those with disabling motor fluctuations unresponsive to oral therapies. This retrospective observational study evaluated the long-term outcomes of LCIG in 52 patients treated between 2010 and 2014, with up to 10 years of follow-up. At 10 years, 67% remained on therapy and 77% were alive. LCIG reduced “off” time by an average of 3.9 h/day at 1 year and sustained partial motor benefit over time. Treatment discontinuation and mortality were associated with cognitive decline and older age at initiation. Although LCIG dose requirements increased over time, the total dopaminergic load remained stable. Adverse events occurred in most patients but rarely led to treatment discontinuation. These findings suggest that LCIG offers sustained efficacy, high long-term treatment retention, and a manageable safety profile, supporting its role as a durable therapeutic option for carefully selected aPD patients.
Indexed as
Identifiers
41591598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.